HomeAI · summaries
Storia in 4 fonti
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
Confronto fonti
4 prospettive sulla stessa storiaTimeline cronologica
- ·
statnews.com
Longevity startup NewLimit raises $435 million ahead of first clinical trial
Longevity startup NewLimit plans to launch its first clinical trial of a liver medicine after raising a staggering $435 million in new funding.
- ·
endpoints.news
Anti-aging startup NewLimit raises $435M at $3B+ valuation, eyes clinic in 2027
NewLimit said Tuesday it has raised a $435 million Series C round at a $3.1 billion post-money valuation.
- ·
biopharmadive.com
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis…
- ·
qz.com
NewLimit raises $435M Series C, valuation hits $3.1B
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy next year